Although no preclinical studies in melanoma have been published to date evaluating the efficacy of a pan-CDK2/4/6 inhibitor or the combination of a CDK4/6 inhibitor with a CDK2 inhibitor, studies have explored the impact of CDK2 inhibition on melanoma growth control [68]. Here, CDK4 is linked to melanoma.